Cargando…
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a transmembrane protein expressed on normal and malignant B cells. This open-label, phase Ib, dose-escalation study was conducted to determine the recommended phase II dose (RP2D) of BI 836826 + ibrutinib in patients with relapsed/re...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279974/ https://www.ncbi.nlm.nih.gov/pubmed/33683501 http://dx.doi.org/10.1007/s10637-020-01056-4 |
_version_ | 1783722555550466048 |
---|---|
author | Danilov, Alexey V. Spurgeon, Stephen E. Siddiqi, Tanya Quinson, Anne-Marie Maier, Daniela Smith, Dionne Brown, Jennifer R. |
author_facet | Danilov, Alexey V. Spurgeon, Stephen E. Siddiqi, Tanya Quinson, Anne-Marie Maier, Daniela Smith, Dionne Brown, Jennifer R. |
author_sort | Danilov, Alexey V. |
collection | PubMed |
description | BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a transmembrane protein expressed on normal and malignant B cells. This open-label, phase Ib, dose-escalation study was conducted to determine the recommended phase II dose (RP2D) of BI 836826 + ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Eligible patients received 420 mg/day of ibrutinib with escalating doses of BI 836826. BI 836826 was administered in 4-week cycles. After Cycle 12, patients achieving complete response (CR), CR with incomplete marrow recovery, or minimal residual disease-negative partial response could continue to receive BI 836826 + ibrutinib every 4 weeks for ≤ 12 additional cycles. Patients received either 100 mg (n = 3) or 200 mg (n = 3) BI 836826 + ibrutinib. In the 100 mg BI 836826 cohort, one patient received two cycles and two patients received 22 cycles of BI 836826. In the 200 mg BI 836826 cohort, patients received 12, 16 and 20 cycles of BI 836826, respectively. All patients discontinued BI 836826 and continued ibrutinib outside the trial. No dose-limiting toxicities were reported in the maximum tolerated dose (MTD) evaluation period. As the trial was discontinued before the MTD was reached, the RP2D was not determined. Grade 3/4 adverse events (AEs) were predominantly hematological. Pseudomonal bacteremia was the only drug-related AE of special interest. BI 836826 + ibrutinib did not exceed the MTD at doses up to 200 mg in patients with CLL. However, RP2D and MTD were not formally established, as the sponsor discontinued the trial. |
format | Online Article Text |
id | pubmed-8279974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-82799742021-07-20 A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia Danilov, Alexey V. Spurgeon, Stephen E. Siddiqi, Tanya Quinson, Anne-Marie Maier, Daniela Smith, Dionne Brown, Jennifer R. Invest New Drugs Phase I Studies BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a transmembrane protein expressed on normal and malignant B cells. This open-label, phase Ib, dose-escalation study was conducted to determine the recommended phase II dose (RP2D) of BI 836826 + ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Eligible patients received 420 mg/day of ibrutinib with escalating doses of BI 836826. BI 836826 was administered in 4-week cycles. After Cycle 12, patients achieving complete response (CR), CR with incomplete marrow recovery, or minimal residual disease-negative partial response could continue to receive BI 836826 + ibrutinib every 4 weeks for ≤ 12 additional cycles. Patients received either 100 mg (n = 3) or 200 mg (n = 3) BI 836826 + ibrutinib. In the 100 mg BI 836826 cohort, one patient received two cycles and two patients received 22 cycles of BI 836826. In the 200 mg BI 836826 cohort, patients received 12, 16 and 20 cycles of BI 836826, respectively. All patients discontinued BI 836826 and continued ibrutinib outside the trial. No dose-limiting toxicities were reported in the maximum tolerated dose (MTD) evaluation period. As the trial was discontinued before the MTD was reached, the RP2D was not determined. Grade 3/4 adverse events (AEs) were predominantly hematological. Pseudomonal bacteremia was the only drug-related AE of special interest. BI 836826 + ibrutinib did not exceed the MTD at doses up to 200 mg in patients with CLL. However, RP2D and MTD were not formally established, as the sponsor discontinued the trial. Springer US 2021-03-08 2021 /pmc/articles/PMC8279974/ /pubmed/33683501 http://dx.doi.org/10.1007/s10637-020-01056-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Phase I Studies Danilov, Alexey V. Spurgeon, Stephen E. Siddiqi, Tanya Quinson, Anne-Marie Maier, Daniela Smith, Dionne Brown, Jennifer R. A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia |
title | A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia |
title_full | A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia |
title_fullStr | A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia |
title_full_unstemmed | A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia |
title_short | A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia |
title_sort | phase ib, open label, dose escalation trial of the anti-cd37 monoclonal antibody, bi 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia |
topic | Phase I Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279974/ https://www.ncbi.nlm.nih.gov/pubmed/33683501 http://dx.doi.org/10.1007/s10637-020-01056-4 |
work_keys_str_mv | AT danilovalexeyv aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT spurgeonstephene aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT siddiqitanya aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT quinsonannemarie aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT maierdaniela aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT smithdionne aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT brownjenniferr aphaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT danilovalexeyv phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT spurgeonstephene phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT siddiqitanya phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT quinsonannemarie phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT maierdaniela phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT smithdionne phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia AT brownjenniferr phaseibopenlabeldoseescalationtrialoftheanticd37monoclonalantibodybi836826incombinationwithibrutinibinpatientswithrelapsedrefractorychroniclymphocyticleukemia |